IRWD Live signals | Maximize Profits with Getagraph.com

BUY 157742 min ago

@ $15.52

Issued: 14 Feb 2024 @ 13:33

Return: -59.41%

Previous signal: Feb 13 - 14:42

Previous signal: Sell

Return: 2.37 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	2.61M
Average Volume	3.69M
Market Cap	1.00B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.930
ATR14	$0.0110 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Mccourt Thomas A	Sell	67 618	Class A Common Stock
2024-05-20	Davis Andrew	Sell	22 725	Class A Common Stock
2024-05-20	Shetzline Michael	Sell	16 128	Class A Common Stock
2024-05-20	John Minardo	Sell	17 404	Class A Common Stock
2024-05-16	Emany Sravan Kumar	Sell	18 280	Class A Common Stock

INSIDER POWER
38.46
Last 100 transactions
Buy: 2 661 332 \| Sell: 1 066 794

Volume Correlation

Long: -0.50 (weak negative)

Short: -0.52 (weak negative)

Signal:(40.709) Neutral

Ironwood Pharmaceuticals Correlation

10 Most Positive Correlations
NERV	0.95
LUNG	0.948
SMSI	0.927
ANIX	0.903
WKME	0.902
MODV	0.9
ELTK	0.899
RAPT	0.899
DBX	0.898
EEIQ	0.896

10 Most Negative Correlations
BZFD	-0.957
IINN	-0.92
SSIC	-0.919
ACVA	-0.916
MRVI	-0.914
IPKW	-0.909
PPC	-0.907
PUBM	-0.905
HOOD	-0.904
ROOT	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ironwood Pharmaceuticals Correlation - Currency/Commodity

-0.43
( neutral )

0.29
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.11
( neutral )

Ironwood Pharmaceuticals Financials

Annual	2023
Revenue:	$442.74M
Gross Profit:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2023
Revenue:	$442.74M
Gross Profit:	$441.16M (99.64 %)
EPS:	$-6.45

FY	2022
Revenue:	$410.60M
Gross Profit:	$409.18M (99.65 %)
EPS:	$1.130

FY	2021
Revenue:	$413.75M
Gross Profit:	$413.75M (100.00 %)
EPS:	$3.26

Financial Reports:

No articles found.

Ironwood Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.